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Parenteral vaccinationBoosting BCG using heterologous prime-boost represents a promising strategy for improved tuberculosis
(TB) vaccines, and adenovirus (Ad) delivery is established as an efficacious boosting vehicle. Although
studies demonstrate that intranasal administration of Ad boost to BCG offers optimal protection, this is
not currently possible in cattle. Using Ad vaccine expressing the mycobacterial antigen TB10.4 (BCG/
Ad-TB10.4), we demonstrate, parenteral boost of BCG immunised mice to induce specific CD8+ IFN-c pro-
ducing T cells via synergistic priming of new epitopes. This induces significant improvement in pul-
monary protection against Mycobacterium bovis over that provided by BCG when assessed in a
standard 4 week challenge model. However, in a stringent, year-long survival study, BCG/Ad-TB10.4
did not improve outcome over BCG, which we suggest may be due to the lack of additional memory cells
(IL-2+) induced by boosting. These data indicate BCG-prime/parenteral-Ad-TB10.4-boost to be a promis-
ing candidate, but also highlight the need for further understanding of the mechanisms of T cell priming
and associated memory using Ad delivery systems. That we were able to generate significant improve-
ment in pulmonary protection above BCG with parenteral, rather than mucosal administration of boost
vaccine is critical; suggesting that the generation of effective mucosal immunity is possible, without
the risks and challenges of mucosal administration, but that further work to specifically enhance sus-
tained protective immunity is required.
Crown Copyright  2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction It is clear that optimal protection against TB requires CD4 TTuberculosis (TB) caused by infection with Mycobacterium
tuberculosis orMycobacterium bovis remains one of the most impor-
tant infectious diseases of man and animals, respectively; inflicting
a huge cost in both health, welfare and financial terms [1]. At pre-
sent the only available vaccine against TB is M. bovis bacille
Calmette-Guérin (BCG), which demonstrates variable efficacy in
humans and cattle [2,3]. Despite this inconsistent performance,
BCG remains one of the most widely used human vaccines in the
world and due to its partial efficacy and proven safety record, is
unlikely to be withdrawn. Hence, a great deal of research effort is
targeted towards improving the efficacy of BCG by a number of
approaches; prominent among which is boosting BCG with
heterologous vaccines [4,5].cells, as well as the effector cytokines IFN-c and TNF-a [reviewed
in 6]. However, as other studies demonstrate, CD4 T cell derived
IFN-c is not an exclusive component of vaccine-mediated immu-
nity [7] and identification of other critical components of protec-
tion remains elusive. The role of CD8 T cells in protection against
TB is somewhat less clear and as yet poorly defined [6].
A number of viral heterologous boost vehicles for tuberculosis
vaccines have been evaluated [reviewed in 8], with modified Vac-
cinia Ankara (MVA) and Adenovirus (Ad) recently progressing to
clinical trials [9,10].
We previously reported the efficacy of an ESAT-6 protein family
member, RV3019c as a subunit vaccine against bovine TB [11].
Another member of this family, RV0288 (TB10.4) [12], has been
found to be highly immuno-dominant in BCG immunised,M. tuber-
culosis [13] and M. bovis infected mice [14,15] and human TB
patients [12]. As this antigen is expressed by BCG, M. tuberculosis
and M. bovis, it may therefore represent an ideal candidate as a
boost vaccine following BCG immunisation. Indeed, studies have
reported the efficacy of multivalent adenoviral vaccines incorpo-
rating TB10.4 against both M. tuberculosis [16–19] and M. bovis
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nasal/respiratory delivery to be optimal, given the One Health
approach of our research, and that respiratory vaccination remains
a technical challenge in bovines, we wished to evaluate the poten-
tial of Ad expressing TB10.4 as an injectable BCG boost in a murine
model of immunity against M. bovis.
We first established the efficacy of TB10.4 protein vaccination
against M. bovis, then expressed TB10.4 in type 5 Ad (Ad-TB10.4).
We subsequently parentally boosted BCG induced immunity with
Ad-TB10.4. BCG/Ad-TB10.4 prime-boost increased the frequency
of CD8+ IFN-c+ T cells via recognition of additional epitopes, but
not the frequency of multifunctional CD4+ or CD8+ T cells. Signifi-
cantly, systemic boosting increased pulmonary protection against
an M. bovis challenge. Despite this encouraging increase in protec-
tion, long term survival was unchanged, which we suggest may
be due to the lack of additionalmemory cell (IL-2+) responses. These
data indicate BCG-prime/parenteral-Ad-TB10.4-boost to be a
promising candidate for future development, but also highlight
the need for further understanding of the mechanisms by which
vaccination induces more effective and sustained protective immu-
nity against TB.2. Materials and methods
2.1. Ethics
All animal work was carried out in accordance with the UK Ani-
mal (Scientific Procedures) Act 1986; under appropriate licences.
The study protocol was approved by the APHA Animal Use Ethics
Committee (UK PCD number 70/6905).
2.2. Animals
Female BALB/c mice were obtained from SPF facilities at Charles
River UK Ltd. and used at 8 weeks of age. All animals were housed
in appropriate Advisory Committee on Dangerous Pathogens
(ACDP) Containment Level 3 (equivalent to BSL3) facilities at APHA,
according to the Code of Practice for the Housing and Care of Ani-
mals Bred, Supplied or Used for Scientific Purposes [21]. All ani-
mals were randomly assigned to treatment groups, and group
housed (6 or 8 mice per cage, as specified below), with water
and food ad libitum and provided with maximum environmental
enrichment (e.g. toys, nesting and seeds) as was possible under
biological containment. For immunological analyses, provision of
normally distributed data required minimum sample size n = 6
(Kolmogorov and Smirnov test). For enumeration of bacterial load,
n = 8 is the minimum required to detect a 0.5 log reduction, at 95%
power, assuming a standard deviation of 0.25 log10 based on pre-
vious laboratory data. Similar rationale was used for use of n = 8 in
‘survival’ analyses groups.
After challenge with M. bovis, all mice were weighed twice
weekly and assessed for clinical signs of tuberculosis daily. Clinical
signs of tuberculosis in mice manifest as: weight loss, hunching,
piloerection, unresponsiveness to stimuli and difficulty breathing.
Animals were scored daily for any of these clinical criteria using
an in-house scoring system approved by the APHA Named Veteri-
nary Surgeon (NVS) and UK Home Office Animal Inspectorate, and
specified in the relevant licences. Animals were euthanized at a
pre-determined humane endpoint based on these clinical criteria.
2.3. Mycobacteria, mycobacterial enumeration and antigens
The vaccination strain was the human vaccine M. bovis BCG
Danish 1331 prepared as per manufacturer’s instructions (SSI,
Copenhagen, Denmark). M. bovis strain AF2122/97 was used forall challenge experiments as described [14]. Recombinant
mycobacterial protein TB10.4 (Proteix sro, Prague, Czech Republic)
was used for immunisation and stimulation as described [14].
Additionally, peptides mapping TB10.4 were used for ELISPOT
stimulation (Pepscan, Lelystad, The Netherlands). 13 of the possi-
ble 14 peptides (16mers, overlapping by 10 aa; no peptide was
available for P7) mapping the entire protein sequence were used
individually, or as a pool.
Mycobacteria were enumerated in aseptically removed spleen
and lungs from animals after euthanasia. Organs were homoge-
nised, serially diluted and plated out onto modified Middlebrook
7H11 agar medium as previously described [22]. Bacterial colonies
were enumerated four weeks later following incubation at 37 C.
CFU data were log transformed (Y = log[Y]) and expressed as
log10/organ.2.4. Adenovirus-TB10.4 construction
The mycobacterial gene TB10.4 was amplified from M. tubercu-
losis H37Rv genomic DNA using primers: Rv0288 BamF (GCGGATC-
CATGTCGCAAATCATGTACAAC, BamHI site) and Rv0288 XBAR
(ATTATCTAGACTAGCCGCCGCCCCATTTGGCGGCTTC, XBAI site).
The amplification conditions were: 94 C for 15 s, followed by 30
cycles of 15 s at 94 C, hybridization and extension at 68 C for
3 min, then a final extension for 3 min at 68 C. PCR products and
adenoviral shuttle vector pVQ Ad5CMV K were digested with
BamHI and XBaI, ligated following standard protocols, and trans-
formed into E. coli DH5a. Sequencing was used to confirm the cor-
rect sequence and orientation of the cloned fragments. Subsequent
cloning of pVQ Ad5CMV-RV0288 into pVQ HuAd5 backbone and
amplification was performed by Viraquest Inc. (North Liberty,
Iowa), as described [23].2.5. Immunisation and challenge
2.5.1. Protein vaccinations
The protein sub-unit vaccination/challenge schedule is summa-
rized in Fig. 1A. Mice (n = 8) were immunised via the sub-
cutaneous route (s.c.) three times (two weeks apart) with 100 ll
containing 10 lg of TB10.4 (RV0288) protein emulsified in MPL/
DDA adjuvant consisting of 25 lg detoxified Lipid A (MPL) (Avanti
polar Lipids, Alabaster, Alabama), dissolved in 0.2% triethylamine.
This was mixed by multiple syringing with 250 lg of dimethyl-
dioctadecyl ammonium bromide (DDA) micelles (created by heat-
ing to 80 C, E. Agger SSI, pers. comm.) (both Sigma, Poole, UK).
Control mice were immunised with MPL-DDA adjuvant alone. A
separate group of mice were immunised with a single injection
of 2  105 Colony Forming Units (CFU) of BCG intradermally (i.d.)
in the base of the tail. Four weeks following final sub-unit immu-
nisation, mice were challenged via intravenous route (i.v.) which
is less stringent than intranasal challenge [24], with 1000 CFU of
M. bovis. Four weeks later they were euthanized, and lungs and
spleens removed for bacterial enumeration.2.5.2. Ad-TB10.4 dose response
Mice (n = 3), were immunised with 100 ll containing: 5  106,
5  107 or 5  108 Plaque Forming Units (PFU) of Ad-TB10.4
or Ad-empty, (i.d.) in the base of the tail. Twelve days
post-immunisation (p.i.) they were euthanized and spleen cells
prepared. Specific CD4+ T cell responses were assessed using
intracellular staining (ICS) as previously described [14], following
stimulation with 2 lg/ml TB10.4 protein.
Fig. 1. Vaccination regimen schedules. Mice were immunised with BCG, TB10.4/
adjuvant or adjuvant alone and bacterial burden assessed 4 weeks after intravenous
challenge with 1000 CFU of M. bovis (A). BCG immunised or naïve mice were
boosted i.d. with two doses of either Ad-TB10.4 or Ad-empty and the immune
status was evaluated prior to challenge (B). Bacterial burden and survival rate in
BCG Prime-Boost immunised mice were assessed after intranasal challenge with
300 CFU of M. bovis (C).
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The prime-boost vaccination/challenge schedule is summarized
in Fig. 1B and C. There were six separate treatment groups (n = 22/
group) of mice: Placebo; BCG; BCG/Ad-TB10.4; BCG/Ad-empty;
Ad-TB10.4 and Ad-empty. Groups of mice were immunised with
a single injection (50 ll) containing 2  105 CFU of BCG, i.d. in the
base of the tail. Six weeks later groups of placebo or BCG immu-
nisedmice were boosted twice four weeks apart, in the same location
with 5  107 PFU (50 ll) of Ad-TB10.4 or Ad-empty. Four weeks
later, six mice per group were euthanized for immunological anal-
yses, and all remaining mice were challenged via the intranasal
route (i.n.) with 300 CFUM. bovis as previously described [24]. Bac-
terial loads in spleen and lungs in eight mice per group were enu-
merated four weeks after challenge as previously described above,
and for survival data, eight mice per group were monitored for a
further 318 days post challenge, or until clinical manifestations
of TB necessitated euthanisation at a humane endpoint according
to a pre-determined clinical scoring system.
2.6. Cell isolation and stimulation
Following euthanasia, spleens were aseptically removed and
cells prepared as previously described [14]. Following washing
(300 g/8 mins), all cells were re-suspended at 5  106/ml for
assays. Cells were cultured with specific antigen as stated, with
each individual protein or peptide antigen at a final concentration
of 2 lg/ml for all assays.
2.7. IFN-c ELISPOT
Cells were incubated with TB10.4 protein, a pool of TB10.4 pep-
tides, or the individual peptides as stated and the frequency ofantigen-specific IFN-c secretors (expressed as Spot Forming Units
or SFU) detected by ELISPOT (Mabtech, Sweden), as previously
described [14].
2.8. Cytokine production
Cells (5  106/ml) were cultured in the presence of antigen
(TB10.4 protein) for 72 h (37 C/5% CO2) prior to harvest of super-
natant. Production of IFN-c, TNF-a, IL-2, IL-4, IL-6, IL-10, IL-12, and
IL-17 was measured by multiplex chemi-luminescent ELISA using
the Meso Scale Discovery platform (MSD, Rockville, Maryland)
according to manufacturer’s instructions.
2.9. Flow cytometry
For intracellular staining (ICS), cells were stimulated with anti-
gen (TB10.4 protein) and anti-CD28 (BD Biosciences, Oxford, UK) as
previously described [14]. They were surface stained with pre-
titrated antibodies: CD4-Brilliant Violet (BV) 711, CD44-BV785,
CD62L-BV605, CD25-BV421, CD19-Alexa Fluor (AF) 700, TER119-
AF700 (all Biolegend, London, UK), CD8-APC-H7 (BD Bioscience),
CD16/32-AF700, CD3-FITC, CD27-PE and LIVE/DEAD Fixable Yel-
low Dead Cell Stain (‘YeViD’, Life Technologies, Paisley, UK). Subse-
quently, cells were washed, fixed/permeabilized and stained by ICS
with IFN-c-APC (BD Bioscience), IL-2-PE-Cy7 and TNF-a-FITC as
previously described [14]. For MHC class II-peptide tetramer stain-
ing, spleen cells were enriched for CD4 T cells (>90% purity) using
the Dynal Mouse CD4 Negative Isolation Kit (Life Technologies) as
per manufacturer’s instructions. Cells were then stained
(45 min/37 C/5% CO2) in culture media with TB10.4 peptide:
MHCII I-A(d) (SSTHEANTMAMMARDT) tetramer-complex, labeled
with APC; or I-A(d) negative control (PVSKMRMATPLLMQA)
tetramer-APC (both provided by NIH Tetramer Core Facility,
Atlanta, Georgia). Following washing, they were stained
(15 min/4 C) in staining buffer with CD4-Brilliant Violet (BV)
711, CD44-BV785, CD62L-BV605, CD25-BV421, CD19-Alexa Fluor
(AF) 700, TER119-AF700, CD8-APC-H7, CD16/32-AF700, CD3-FITC,
CD45RB-PE, and YeViD, washed and fixed with Cytofix (BD Bio-
science). All antibody conjugates were purchased from eBioscience
(Hatfield, UK) except where stated. Data were acquired using a
SORP LSR Fortessa (BD Bioscience) (utilizing a 532 nm laser for
PE and PE-Cy7) and analysed on Flowjo v.10.0.7 (Tree Star, USA)
software. All analyses were gated on a minimum of 100,000 live
lymphocytes.
2.10. Statistical analysis
Non-survival data were analysed by 1-way ANOVA with Bonfer-
roni’s post hoc test, using GraphPad Prism 5 software (GraphPad,
USA). Prior to analysis, mycobacterial counts were log10 trans-
formed and ELISA/ELISPOT data were normalised by subtracting
the unstimulated from the antigen-stimulated culture values. Sur-
vival data was analysed with the Mantel-Cox Log Rank test. Differ-
ences with a q < 0.05 (or q = 0.06 for survival data) were
considered significant and denoted with ⁄, q < 0.01 with ⁄⁄,
q < 0.001 with ⁄⁄⁄ and q < 0.0001 with ⁄⁄⁄⁄.3. Results
3.1. TB10.4 induces significant protection against virulent
mycobacterial challenge as a protein subunit vaccine
As an immuno-dominant antigen in BCG immunised mice
[14,15], we investigated the potential of TB10.4 as a protective
vaccine antigen for bovine TB, with a view for use in a BCG
Fig. 2. TB10.4 induces significant protection against virulent mycobacterial chal-
lenge as a protein subunit vaccine. Mice (n = 8) were immunised once i.d. with BCG,
or three times s.c. with the indicated vaccine. Spleen and Lungs from individual
mice were removed 4 weeks following challenge and bacteria enumerated. Data
represent the mean bacterial burden per organ ± SE. *q < 0.05, ***q < 0.001 vs
adjuvant controls; ANOVA with Bonferroni’s post hoc test. Data are representative of
one of two independent experiments.
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with TB10.4 emulsified in adjuvant or with a single dose of BCG.
Mice were challenged 1 month after final immunisation and lung
bacterial load measured 4 weeks later. Intravenous (i.v.) challenge,
which is less stringent than intranasal challenge [24], and our pre-
ferred model for evaluating non-BCG component vaccines, was
employed in this study. As shown in Fig. 2, TB10.4 induced signif-
icant protection (0.64 Log10, q < 0.05 vs adjuvant control) in the
lungs, as did BCG (1.43 Log10, q < 0.001 vs adjuvant control). In
the spleen protection induced by TB10.4 was less, but still signifi-
cant (0.30 Log10, q < 0.05), compared to BCG (1.8 Log10, q < 0.001 vs
adjuvant control). These data clearly indicate the potential for
TB10.4 as a protective antigen for M. bovis challenge.
3.2. Optimisation of Ad-TB10.4 dose
Having demonstrated the potential of TB10.4 as a protective
sub-unit vaccine, we cloned TB10.4 into pVQ Ad5 vector to produce
Ad-TB10.4 vaccine as described in Material & Methods. The opti-
mum dose of Ad-TB10.4 for subsequent use in prime-boost exper-
iments was determined by dose-titration. Mice (n = 3) were
immunised once with 5  106, 5  107 or 5  108 PFU of Ad-
TB10.4 or 5  108 PFU Ad-Empty control and immune responses
assessed 12 days later. ICS analyses (Fig. S2) revealed that whilst
5  106 and 5  108 PFU induced significant frequencies of CD4+
IFN-c+ cells (q < 0.01 and q < 0.05, respectively) compared to the
control vector, 5  107 PFU induced the highest frequency,
although not quite significant (q = 0.07). No CD8+ response was
observed (data not shown). Thus, 5  107 PFU was chosen as the
dose for further experiments.
3.3. Ad-TB10.4 boosts both IFN-c+ cell frequency, and breadth of
epitope recognition following BCG immunisation
To assess the boosting effect of Ad-TB10.4, BCG immunised or
naïve mice (n = 6) were boosted six weeks after vaccination with
two doses of either Ad-TB10.4 or Ad-empty, as illustrated in
Fig. 2A. In order to ensure maximum effect, the common strategy
[reviewed in 24] of two boosts were used. To establish immune
status prior to challenge, one month after final vaccination, spleen
cells from individual mice in each vaccine regimen were subjected
to IFN-c ELISPOT assay (Fig. 3). As shown in Fig. 3A, BCG induced
higher responses than the PBS control immunisation (425 vs 49
SFU), as did BCG/Ad-empty (583 vs 49 SFU). Interestingly, Ad-
TB10.4 alone, induced a higher response than BCG (1342 SFU,
q < 0.001), indicating the ability of adenovirus delivery to initiate
a strong IFN-c response. Strikingly, Ad-TB10.4 boost synergised
with BCG, inducing significantly higher responses (2171 SFU) than
any other regimen (q < 0.001 vs all groups) and 50% higher than
Ad-TB10.4 alone.
In addition, we examined responses of pooled spleen samples
from the BCG, BCG/Ad-TB10.4, BCG/Ad-empty and Ad-TB10.4
groups to 13 individual overlapping peptides mapping the protein
sequence of TB10.4, or a peptide pool. As shown in Fig. 3B, BCG
induced a response to one epitope only (P13-14), whilst the use
of Ad-TB10.4 alone induced the recognition of an additional epi-
tope(s) contained within peptides 3–5 and not that of P13. The
combination of BCG and Ad-TB10.4 did not induce responses to
any epitopes other than the individual vaccine components them-
selves, but boosted responses to peptides 3–5 (but not P13-14) by
50%. BCG/Ad-empty only induced a response to the P13-14
epitope.
The observation that Ad-TB10.4 boosted BCG induced responses
by increasing the breadth of epitope recognition, was further con-
firmed when we examined the frequency of CD4 T cells from indi-
vidual mice in each vaccine regimen specific to the singledominant TB10.4 P13 peptide using an MHC class II tetramer–pep-
tide complex (Fig. 3C). These data show that BCG/Ad-TB10.4 failed
to increase the frequency of tetramer+ (i.e. P13-specific) CD27
CD4+ T cells above that induced by BCG alone, indicating the
increased IFN-c responses in boosted animals were not due to
stimulation of P13-specific CD4 T cells.
3.4. Adenovirus vector immuno-modulates BCG induced CD4+ T cell
responses
To further analyse the immune response initiated by the differ-
ent vaccination regimes, individual spleen cell cultures from each
regimen were cultured with TB10.4 protein and three day super-
natants assayed by chemiluminescent ELISA. As shown in Fig. 4,
BCG initiated a TB10.4-specific recall response to all cytokines
measured, although none were significantly higher than in naïve
control mice (q < 0.001). Surprisingly, and in contrast to the IFN-
c ELISPOT results, BCG/Ad-TB10.4 failed to boost any of these
responses and Ad-TB10.4 alone failed to initiate a substantial recall
response.
In contrast, BCG/Ad-empty increased TB10.4 recall responses:
inducing 100% more IL-4, IL-6 (q < 0.05) and IL-12 (q < 0.001);
300% more IFN-c and IL-10 and a striking 800% more IL-17
(q < 0.001) than BCG alone. These data indicated a strong
immuno-modulatory effect of the Ad-empty boost despite not
being co-administered with BCG.
3.5. Ad-TB10.4 significantly boosts antigen-specific CD8+ but not CD4+
T cells
The capacity of Ad-TB10.4 to boost both CD8 as well as CD4 T
cell responses was interrogated by ICS and flow cytometric analy-
sis (gating strategy Fig. S1). As described in Fig. 5A, and previously
reported [14,15], BCG induced a significant (q < 0.0001 vs control)
frequency of IFN-c+/IL-2+/TNF-a+ multifunctional CD4 T cells. The
frequency of these cells was not boosted by Ad-TB10.4. Contrast-
ingly, BCG immunisation induced a poor antigen-specific CD8 T cell
response, but Ad-TB10.4 boost significantly increased the fre-
quency of both IFN-c+ TNF-a+ bi-functional and of IFN-c+ mono-
functional CD8+ T cells (q < 0.001 vs BCG) by 100% and 500%,
respectively (Fig. 5B). As observed in the initial titration, no CD8+
T cell response to Ad-TB10.4 in the absence of BCG was observed
Fig. 3. Ad-TB10.4 boosts IFN-c+ cell frequency and breadth of epitope recognition.
BCG immunised or naïve mice (n = 6) were boosted six weeks after vaccination with
two doses of either Ad-TB10.4 or Ad-empty, one month apart. Four weeks after final
vaccination, individual mouse spleen cells from each vaccine regimen were
subjected to IFN-c ELISPOT assay after stimulation with the BCG-derived recom-
binant protein TB10.4 (A). Bars represent the mean ± SEM. ***q < 0.001 vs BCG group,
ANOVA with Bonferroni’s post hoc test. Pooled spleen cells from each vaccine
regimen were stimulated with TB10.4 derived peptides to map the response to
individual peptides (B). Bars represent represent mean response of each vaccine
group to individual peptides mapping entire protein sequence. The frequency of
CD4 T cells, from individual mice specific to the single dominant TB10.4 P13 peptide
was examined using an MHC class II tetramer–peptide complex specific for this
peptide (C). Bars represent the mean ± SEM % frequency of tetramer+ cells within
the live CD4+ CD27 T cell population minus the result of the non-specific negative
control tetramer. Data are representative of one of two independent experiments.
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by BCG/Ad-TB10.4 did not include IFN-c+/IL-2+/TNF-a+ multifunc-
tional cells, or indeed any IL-2 producing cells. It was not possible
in this study to extensively phenotype these cells, so whether they
represent a similar TEM population as the BCG-specific CD4 T cells
previously characterised [14,15] remains unclear.3.6. Systemically administered Ad-TB10.4 boosting of BCG induces
significantly higher protection against pulmonary tuberculosis
In order to assess the protective efficacy of these vaccine regi-
mens, one month after the last vaccination all remaining mice
were challenged intranasally with 300 CFU of M. bovis. Bacterial
burden in spleen and lungs were assessed one month later in indi-
vidual mice (n = 8), as illustrated in Fig. 2B. As shown in Fig. 6, this
challenge resulted in a substantialM. bovis burden of: 4.45 Log10 in
the spleen and 6.31 Log10 CFU in the lungs of naïve control mice.
BCG induced protection of 1.55 Log10 in the spleen (q < 0.001 vs
controls) and 1.65 Log10 in the lungs (q < 0.001 vs controls).
BCG boosted by Ad-TB10.4 vaccination was sufficient to
increase this protection by a further 0.66 Log10 in spleen
(q = 0.06 vs BCG), and 0.61 Log10 in the lungs (q < 0.01 vs BCG).
BCG/Ad-empty induced equivalent protection to BCG alone, whilst
Ad-TB10.4 alone failed to induce significant protection.
3.7. Ad-TB10.4 boosting of BCG does not enhance long-term protection
In order to assess the long term protection induced by vaccina-
tion, all remaining mice (n = 7/8) were kept for a further 318 days
post-challenge, or until clinical manifestations of TB necessitated
euthanisation according to a clinical scoring system. Survival,
therefore, was counted as time to humane endpoint. Because of
technical issues, these mice were housed at Specific Animal Patho-
gen Order (SAPO, HSE, UK) Level 4, which precluded any sampling
of these animals for histology, bacterial counts or immune status.
As shown in Fig. 7, BCG increased survival with a Median Survival
Time (MST) of 285 days vs naïve controls MST = 188 days
(q = 0.06). Despite significantly reducing bacterial burden at
4 weeks post-challenge (as shown in Fig. 7), BCG/Ad-TB10.4 vacci-
nation did not further increase survival (MST = 286 days).
4. Discussion
Given the unlikelihood of BCG being removed from use in the
intermediate future, heterologous prime-boost based on prior
BCG immunisation is the most likely scenario for improved TB vac-
cines [5]. This has established an intensive effort to evaluate poten-
tial heterologous boost vaccines, with over 45 candidates tested to
date [reviewed in 25]. Here we report our in-house development
and efficacy testing of a BCG boost vaccine (parenteral Ad-
TB10.4) for bovine TB which under One Health principles is rele-
vant for M. tuberculosis vaccine development.
Much controversy exists regarding the suitability of the most
tested (and therefore safe) HuAd5 serotype used here and many
other studies, for use in an eventual target populations with poten-
tial pre-existing immunity against the vector. We chose Ad5 for its
exceptional safety record, [reviewed in 26] and certainly, there
would be no issue of cattle having prior exposure. For potential
human use, there are now strong incontrovertible data that despite
any pre-existing immunity, Ad5 is still safe and provides an effec-
tive delivery vehicle [10,27].
The ability of boost vaccines to increase the breadth of CD4 T
cell epitope recognition has been documented in HIV vaccines
using DNA/Ad [28], and bovine TB vaccines using BCG/MVA
prime-boost [29]. Also, Billeskov et al. [30], reported that protein
immunisation primed recognition of CD4 T cell epitopes which
are subdominant following BCG immunisation or M. tuberculosis
infection.
The increased epitope recognition was detected by ELISPOT,
which does not discern between IFN-c produced by CD4 and CD8
T cells. That BCG/Ad-TB10.4 was demonstrated by ICS to induce
CD8+, but not enhance CD4+ T cell responses compared to BCG
alone, suggests additional epitopes were CD8+ restricted, further
Fig. 4. Adenovirus vector immuno-modulates BCG induced recall responses. BCG immunised or naïve mice (n = 6) were boosted six weeks after vaccination with two doses of
either Ad-TB10.4 or Ad-empty, one month apart. Four weeks after final vaccination, spleen cells of individual mice from each vaccine regimen were cultured with the BCG-
derived recombinant protein TB10.4, and three day supernatants assayed by chemiluminescent ELISA. Bars represent the mean ± SEM. *q < 0.05, **q < 0.01, ***q < 0.001,
ANOVA with Bonferroni’s post hoc test.
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cells. As protein immunisation increases CD4 T cell epitope recog-
nition [30], perhaps a combination of protein and Ad boosting of
BCG may offer the best strategy for the broadest recognition of T
cell epitopes in future. A recent study [31] demonstrated the
promise of this in a TB vaccine model using an adjuvanted protein
subunit prime-Ad boost, but not in the context of prior BCG
immunisation.
Whilst we still do not fully understand the contribution of indi-
vidual TB10.4 epitopes to protection, the human response to BCG ishighly restricted [12] and thus the Ad-TB10.4 induction of a
broader T cell repertoire to this one protective antigen could still
offer a significant opportunity to improve upon BCG, especially
due to its synergistic effect as a BCG boost.
We have previously described that BCG induces a broad multi-
polarised T cell recall cytokine response (stimulated with a defined
cocktail of antigens) [32], and here we demonstrate a similar
response stimulated by TB10.4 in the cell culture supernatant
assay. This is a consistent observation both in our model and pre-
vious reports [31,32] and may indicate such a broad response is
Fig. 5. Ad-TB10.4 significantly boosts antigen-specific CD8+ but not CD4+ T cells.
BCG immunised or naïve mice (n = 6) were boosted six weeks after vaccination with
two doses of either Ad-TB10.4 or Ad-empty, one month apart. Four weeks after final
vaccination, spleen cells of individual mice from each vaccine regimen were
stimulated with the BCG-derived recombinant protein TB10.4, stained by intracel-
lular cytokine staining (ICS) and interrogated by flow cytometry. Graphs represent
the percentage of live CD4+ (A) and CD8+ (B) lymphocytes detected in the analysis,
as determined by the inclusion of a LIVE/DEAD fixable yellow dead cell stain. Plots
were gated as described in Supplementary Fig. S1 and analysed for all combinations
of simultaneous IFN-c, IL-2 and TNF-a production. Bars represent the mean ± SEM.
**p < 0.01; ANOVA with Bonferroni’s post hoc test. Data are representative of one of
two independent experiments.
Fig. 6. Systemically administered Ad-TB10.4 boosting of BCG induces significantly
higher protection against pulmonary tuberculosis. BCG immunised or naïve mice
(n = 6–8) were boosted i.d. six weeks after vaccination with two doses of either Ad-
TB10.4 or Ad-empty, one month apart. Spleen and Lungs from individual mice were
removed 4 weeks following challenge and bacteria enumerated. Data represent the
mean bacterial burden per organ ± SE. *q < 0.05; **q < 0.005; ***q < 0.0005; vs control
or BCG; ANOVA with Bonferroni’s post hoc test.
Fig. 7. Ad-TB10.4 boosting of BCG fails to enhance long-term protection. Mice
(n = 7/8) were infected with 300 CFU of M. bovis i.n. and kept until clinical
manifestations of TB necessitated euthanisation according to a clinical scoring
system. Survival was counted as time to humane endpoint, or until the end of
experiment at 318 days post-challenge. Survival data was analysed with the
Mantel-Cox Log Rank test; *q = 0.06.
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IFN-c production in the culture assay, was surprising given the
significant IFN-c ELISPOT responses observed. This may reflect
different parameters measured (secretor frequency vs magnitude;
effector vs memory), and that ELISPOT is more sensitive [33];
detecting immediate/short-term IFN-c release, accumulatively.
The disparity between IFN-c detection by ELISPOT and ICS, may
be due to: (i) the fact that peptides were used for the
IFN-c-ELISPOT stimulation, whilst ICS used protein; therefore,
insufficient antigen-processing may occur to present the specific
epitopes revealed in the epitope mapping, or (ii) assay sensitivity.
The immunomodulatory effect of the Ad-empty vector adminis-
tration on the TB10.4-specific BCG response was also surprising,
but is likely due to a non-specific adjuvant effect. Analysis of total
virus particles in batches of Ad-TB10.4 & Ad-empty revealed no
differences, and therefore does not explain this differential effect.
It is known that Ad vectors induce innate responses [34], and data
demonstrate BCG to persist long after vaccination [35–37]. Com-
bined with previous reports [38–40], we propose the Ad vector isadjuvanting persistent BCG, enhancing specific immune responses.
The exact mechanisms of this adjuvant effect are not yet known
but are the subject of current studies. These responses together
with a lack of additional protection in this group, supports the
increasingly established hypothesis that increasing the magnitude
of responses alone is not beneficial [41,42].
In light of this vector adjuvant effect on CD4 T cell responses, it
was equally intriguing that Ad-TB10.4 failed to do the same. Eluci-
dating the mechanisms of this observation was beyond the scope
4010 D.A. Kaveh et al. / Vaccine 34 (2016) 4003–4011of this study, but we propose two potential explanations. First, the
antigen-specific CD8 T cells identified here may dominate the
response to Ad-TB10.4, thus down-regulating CD4 T cell responses.
Alternatively, peripheral negative selection may occur [43]. The
initial Ad-TB10.4 boost may have primed very high affinity
TB10.4-specific CD4 T cells, which undergo apoptosis upon subse-
quent boost, by peripheral repertoire tuning.
The increase in pulmonary protection over BCG achieved by
BCG/Ad-TB10.4 immunisation compares to other non-mucosal
prime-boost vaccine regimes performed in mice using a similar
vaccination-challenge interval (reviewed in [25]). This is however,
to our knowledge, the first demonstration of efficacy using a sys-
temic Adenoviral boost in mice.
The reason for our study demonstrating efficacy with non-
respiratory adenoviral boost where others have failed is at this
point unclear, although a recent study in non-human primates
(NHP) has shown equivalent efficacy between respiratory and par-
enteral Ad-Ag85A boost of BCG [44]. There are several potential
factors which may explain this discrepancy with many published
studies. Importantly, our study challenged with M. bovis which
although an order of magnitude more virulent than M. tuberculosis
in mice (Hogarth, P.J., unpublished data, [45]) is the parent strain of
BCG & thus more closely related than M. tuberculosis [46]. Our
boost vaccine (Ad-TB10.4) has not previously been tested using
either i.d. route or multiple boost. It is also one of few boost vacci-
nes to show improvement upon BCG which is not RV3804c
(Ag85A) [25] specific; thus, there is potential for improved efficacy
if used in a multivalent/combined vaccine formulation with Ag85A
and other protective antigens.
That improved protection did not translate into enhanced sur-
vival was disappointing, although a common feature of many stud-
ies [25]. We propose that the absence of IL-2 producing CD8+ cells
may indicate the lack of memory phenotype [47]. In this case, addi-
tional protection may be limited to the failure of short-term pro-
tective responses to persist. We are currently investigating
alternate immunisation regimes to boost immune memory and
thus longer term protection.
This study indicates BCG/Ad-TB10.4 prime-boost to be a
promising candidate, but also highlights the need for further
understanding of the mechanisms of T cell priming and associated
memory using adenovirus delivery systems. The fact that we were
able to generate significant improvement over BCG with a par-
enteral, rather than mucosal administered boost is of great pro-
mise, demonstrating effective mucosal immunity is possible
without the risks and challenges of mucosal administration.
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